Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
ApoRx is a drug-discovery company focusing on the discovery, design, characterization, and development of small proteolysis-targeting molecules against well-validated disease-causing proteins in cancer and other indications.
The core of its technology is the Aperion library, a proprietary focus library of RING E3 ligase binders that is designed to harness the intracellular ubiquitin-proteasome machinery to degrade and destroy unwanted proteins via targeted protein degradation.
ApoRx is a subsidiary of Agbiopro Protein Degradation Hub, a management and consulting firm.